115 related articles for article (PubMed ID: 21535409)
1. Ramiprilate inhibits functional matrix metalloproteinase activity in Crohn's disease fistulas.
Efsen E; Saermark T; Hansen A; Bruun E; Brynskov J
Basic Clin Pharmacol Toxicol; 2011 Sep; 109(3):208-16. PubMed ID: 21535409
[TBL] [Abstract][Full Text] [Related]
2. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype.
Meijer MJ; Mieremet-Ooms MA; van der Zon AM; van Duijn W; van Hogezand RA; Sier CF; Hommes DW; Lamers CB; Verspaget HW
Dig Liver Dis; 2007 Aug; 39(8):733-9. PubMed ID: 17602907
[TBL] [Abstract][Full Text] [Related]
3. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.
Kirkegaard T; Hansen A; Bruun E; Brynskov J
Gut; 2004 May; 53(5):701-9. PubMed ID: 15082589
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand.
Menchén L; Marín-Jiménez I; Arias-Salgado EG; Fontela T; Hernández-Sampelayo P; Rodríguez MC; Butta NV
Gut; 2009 Jul; 58(7):920-8. PubMed ID: 19039088
[TBL] [Abstract][Full Text] [Related]
5. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
6. Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab.
Di Sabatino A; Saarialho-Kere U; Buckley MG; Gordon JN; Biancheri P; Rovedatti L; Corazza GR; Macdonald TT; Pender SL
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1049-55. PubMed ID: 19357521
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures.
Di Sabatino A; Jackson CL; Pickard KM; Buckley M; Rovedatti L; Leakey NA; Picariello L; Cazzola P; Monteleone G; Tonelli F; Corazza GR; MacDonald TT; Pender SL
Gut; 2009 Jun; 58(6):777-89. PubMed ID: 19201776
[TBL] [Abstract][Full Text] [Related]
8. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
Ochsenkühn T; Göke B; Sackmann M
Am J Gastroenterol; 2002 Aug; 97(8):2022-5. PubMed ID: 12190171
[TBL] [Abstract][Full Text] [Related]
9. [Entero-enteral fistulas in Crohn disease: radical or conservative surgical treatment of the "victim" segment?].
Saint-Marc O; Frileux P; Sales JP; Faucheron JL; Balladur P; Tiret E; Parc R
Gastroenterol Clin Biol; 1994; 18(10):873-9. PubMed ID: 7875396
[TBL] [Abstract][Full Text] [Related]
10. Do anal fistulas in Crohn's disease behave differently and defy Goodsall's rule more frequently than fistulas that are cryptoglandular in origin?
Coremans G; Dockx S; Wyndaele J; Hendrickx A
Am J Gastroenterol; 2003 Dec; 98(12):2732-5. PubMed ID: 14687825
[TBL] [Abstract][Full Text] [Related]
11. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies.
Di Sabatino A; Pender SL; Jackson CL; Prothero JD; Gordon JN; Picariello L; Rovedatti L; Docena G; Monteleone G; Rampton DS; Tonelli F; Corazza GR; MacDonald TT
Gastroenterology; 2007 Jul; 133(1):137-49. PubMed ID: 17631138
[TBL] [Abstract][Full Text] [Related]
12. [Recurrent Crohn's disease in the ileocolonic anastomosis complicated with duodenal fistula].
Ghidirim G; Ignatenco S; Mişin I; Gagauz I; Tiple I; Cuţitari I; Zastavniţchi G
Chirurgia (Bucur); 2007; 102(5):607-10. PubMed ID: 18018365
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for the treatment of fistulas in patients with Crohn's disease.
Present DH; Rutgeerts P; Targan S; Hanauer SB; Mayer L; van Hogezand RA; Podolsky DK; Sands BE; Braakman T; DeWoody KL; Schaible TF; van Deventer SJ
N Engl J Med; 1999 May; 340(18):1398-405. PubMed ID: 10228190
[TBL] [Abstract][Full Text] [Related]
14. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension.
Bolbrinker J; Markovic S; Wehland M; Melenhorst WB; van Goor H; Kreutz R
J Pharmacol Exp Ther; 2006 Jan; 316(1):8-16. PubMed ID: 16166267
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A
J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734
[TBL] [Abstract][Full Text] [Related]
16. [Risk factors for the development of fistulas in Crohn disease].
Kruis W; Scheuchenstein AM; Scheurlen C; Weinzierl M
Z Gastroenterol; 1989 Jun; 27(6):313-6. PubMed ID: 2773528
[TBL] [Abstract][Full Text] [Related]
17. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A.
Hanauer SB; Smith MB
Am J Gastroenterol; 1993 May; 88(5):646-9. PubMed ID: 8480725
[TBL] [Abstract][Full Text] [Related]
18. Surgical management of internal fistulas in Crohn's disease.
Saint-Marc O; Tiret E; Vaillant JC; Frileux P; Parc R
J Am Coll Surg; 1996 Aug; 183(2):97-100. PubMed ID: 8696552
[TBL] [Abstract][Full Text] [Related]
19. Intestinal mucosa diamine oxidase activity reflects intestinal involvement in Crohn's disease.
Thompson JS; Burnett DA; Markin RS; Vaughan WP
Am J Gastroenterol; 1988 Jul; 83(7):756-60. PubMed ID: 3132852
[TBL] [Abstract][Full Text] [Related]
20. Morphological characterisation of Crohn's disease fistulae.
Bataille F; Klebl F; Rümmele P; Schroeder J; Farkas S; Wild PJ; Fürst A; Hofstädter F; Schölmerich J; Herfarth H; Rogler G
Gut; 2004 Sep; 53(9):1314-21. PubMed ID: 15306592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
